Edition:
United States

Morphosys AG (MORG.DE)

MORG.DE on Xetra

65.64EUR
11:35am EDT
Change (% chg)

€3.07 (+4.91%)
Prev Close
€62.57
Open
€62.58
Day's High
€66.96
Day's Low
€62.50
Volume
519,900
Avg. Vol
161,032
52-wk High
€66.96
52-wk Low
€32.90

MORG.DE

Chart for MORG.DE

About

MorphoSys AG develops and commercializes antibodies for therapeutic applications. The Company develops drugs using its own research and development, as well as in cooperation with pharmaceutical and biotechnology partners. The Company's operating segments include Proprietary Development and Partnered Discovery. In the Proprietar... (more)

Overall

Beta: 0.73
Market Cap(Mil.): €1,834.43
Shares Outstanding(Mil.): 29.32
Dividend: --
Yield (%): --

Financials

  MORG.DE Industry Sector
P/E (TTM): -- 141.11 17.36
EPS (TTM): -2.51 -- --
ROI: -17.61 2.25 -5.72
ROE: -18.07 0.17 -5.10

BRIEF-Morphosys: Janssen updates on development of guselkumab

* ANNOUNCES THAT ITS LICENSEE JANSSEN REPORTED UPDATES ON DEVELOPMENT OF GUSELKUMAB

5:36am EDT

BRIEF-Morphosys confirms 2017 outlook after Q1 loss widens

* Group revenues amounted to eur 11.8 million, in line with level of q1 of 2016

May 03 2017

BRIEF-Morphosys chief scientific officer takes temporary leave

* Says CSO Marlies Sproll takes temporary leave, Markus Enzelberger to serve as interim CSO

Mar 23 2017

BRIEF-Morphosys reports smaller than expected 2016 EBIT loss

* Group revenues of eur 49.7 million (guidance: eur 47 to 52 million)

Mar 09 2017

BRIEF-Morphosys: new data from two phase 3 studies of guselkumab in plaque psoriasis

* Announces that its licensee janssen has reported new data from two phase 3 studies of guselkumab in plaque psoriasis

Mar 03 2017

More From Around the Web

Earnings vs. Estimates